Iovance Biotherapeutics

Iovance Biotherapeutics, established in 2007 and publicly traded under NASDAQ: IOVA, is a biopharmaceutical company focused on developing innovative cancer immunotherapies. Headquartered in San Carlos, California, the company operates within the pharmaceuticals and healthcare sectors, dedicating its efforts to advancing novel cell therapies. Its core mission revolves around harnessing the power of the immune system to treat patients with solid tumors.

With an employee range of 500-1,000 employees and a presence across 6 locations, Iovance Biotherapeutics is engaged in the clinical-stage development and commercialization of its proprietary tumor-infiltrating lymphocyte (TIL) therapies. These advanced treatments aim to deliver personalized immune cell therapies to patients, targeting various forms of cancer. The company's pipeline includes promising candidates designed to expedite patient responses and approvals, reflecting a commitment to cutting-edge biotechnology and patient care. Meet Iovance Biotherapeutics' team to understand the leadership driving these critical initiatives.

Generating substantial revenue of $285.6M, Iovance Biotherapeutics has a history of significant funding rounds, underscoring investor confidence in its therapeutic approach. The company competes in a dynamic market against entities such as Replimune, Arcus Biosciences, and Kite Pharma, all focused on oncology and advanced treatment modalities. Iovance's strategic focus on next-generation cell therapies positions it as a key player in the evolving landscape of cancer treatment. Explore financial highlights for a detailed overview of its fiscal performance and investment history.